Cirrhosis/Liver Failure News

Patients with cirrhosis and COVID-19 had higher mortality rates than patients with COVID-19 alone, but similar rates as patients with just cirrhosis, according to research published in Gut.

Fecal microbiota transplantation was safe and effective for the treatment of Clostridioides difficile infection in patients with cirrhosis, according to study results.

Newly published research from the United Kingdom demonstrates terlipressin is effective for improving kidney function in hospitalized patients with hepatorenal syndrome type 1.

Select patients with acute-on-chronic liver failure who underwent liver transplantation experienced improved survival, according to study results.

In adolescents, non-alcoholic fatty liver disease correlated with decreased cardiorespiratory fitness, irrespective of BMI, according to recently published results.

In this exclusive video, Nancy S. Reau, MD, section chief of hepatology and associate director of organ transplantation at Rush University Medical Center, discusses some important aspects of treating liver diseases during the COVID-19 pandemic.

Insurance status was independently associated with acute-on-chronic liver failure in patients with cirrhosis in an analysis of data from North America published in Clinical Gastroenterology and Hepatology.

During this COVID-19 pandemic, many scientists have turned their efforts to find either a treatment or vaccine for the infection or trying to better understand the infection.

Changes in diet and microbiota were linked with minimal hepatic encephalopathy and hospitalizations in patients with cirrhosis from Mexico compared with American patients, according to research published in Liver International.

Health-related quality of life scores may be useful prognostic screening tools for patients with cirrhosis, according to research published in The American Journal of Gastroenterology.